USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new case ...

USA News Group Commentary VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism tow ...

Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, April 30, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter 2024. Conference Call & Webcast Date: Thursday, May 9, 2024Ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...

Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights ® Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO, CA and CALGARY, AB, March 7, 2024 -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023. All dollar amounts are expressed in Canadian c ...

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and nine months ended September 30, 2023 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | | | September 30, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2023 | | 2022 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 39,981 | $ | 11,666 | ...

2 ONCOLYTICS BIOTECH INC. Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and six months ended June 30, 2023 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | | | June 30, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2023 | | 2022 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 17,520 ...

[Condensed Interim Consolidated Financial Statements](index=1&type=section&id=Condensed%20Interim%20Consolidated%20Financial%20Statements) [Consolidated Statements of Financial Position](index=2&type=section&id=ONCOLYTICS%20BIOTECH%20INC.%20CONDENSED%20INTERIM%20CONSOLIDATED%20STATEMENTS%20OF%20FINANCIAL%20POSITION) Total assets decreased to **$35.3 million** from **$37.3 million** as of March 31, 2023, driven by reduced marketable securities Key Balance Sheet Items (in thousands of Canadian dollars) | Account | March 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $15,872 | $11,666 | | Marketable securities | $13,798 | $20,472 | | Total current assets | $34,261 | $35,684 | | **Total assets** | **$35,328** | **$37,334** | | **Liabilities** | | | | Accounts payable and accrued liabilities | $2,232 | $3,650 | | Total current liabilities | $2,469 | $3,945 | | **Total liabilities** | **$9,577** | **$10,832** | | **Shareholders' Equity** | | | | Total shareholders' equity | $25,751 | $26,502 | [Consolidated Statements of Loss and Comprehensive Loss](index=3&type=section&id=ONCOLYTICS%20BIOTECH%20INC.%20CONDENSED%20INTERIM%20CONSOLIDATED%20STATEMENTS%20OF%20LOSS%20AND%20COMPREHENSIVE%20LOSS) Q1 2023 net loss improved to **$6.4 million** from **$6.8 million** in Q1 2022, due to lower R&D and increased interest income Quarterly Loss and Expense Comparison (in thousands of Canadian dollars) | Item | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | Research and development | $3,539 | $3,708 | | General and administrative | $3,195 | $2,602 | | Interest income, net | $265 | $18 | | **Net loss** | **($6,437)** | **($6,779)** | | Net comprehensive loss | ($6,440) | ($6,826) | | **Basic and diluted loss per share** | **($0.10)** | **($0.12)** | [Consolidated Statements of Changes in Equity](index=4&type=section&id=ONCOLYTICS%20BIOTECH%20INC.%20CONDENSED%20INTERIM%20CONSOLIDATED%20STATEMENTS%20OF%20CHANGES%20IN%20EQUITY) Shareholders' equity declined in Q1 2023, primarily due to the net loss, partially offset by ATM equity program proceeds Reconciliation of Shareholders' Equity for Q1 2023 (in thousands of Canadian dollars) | Description | Amount | | :--- | :--- | | Balance as at December 31, 2022 | $26,502 | | Net loss and other comprehensive loss | ($6,440) | | Proceeds from 'At the Market' Agreement | $5,552 | | Share issue costs | ($180) | | Share-based compensation expense | $317 | | **Balance as at March 31, 2023** | **$25,751** | [Consolidated Statements of Cash Flows](index=5&type=section&id=ONCOLYTICS%20BIOTECH%20INC.%20CONDENSED%20INTERIM%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) Cash and cash equivalents increased by **$4.1 million** in Q1 2023, driven by financing and investing activities, offset by operating cash usage Cash Flow Summary for Q1 (in thousands of Canadian dollars) | Activity | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | Cash used in operating activities | ($7,829) | ($6,252) | | Cash provided by (used in) investing activities | $6,669 | ($36) | | Cash provided by financing activities | $5,271 | $5,014 | | **Increase (decrease) in cash** | **$4,111** | **($1,274)** | | **Cash and cash equivalents, end of period** | **$15,872** | **$39,483** | [Notes to Condensed Interim Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20Condensed%20Interim%20Consolidated%20Financial%20Statements) Notes provide context on the company's biopharmaceutical operations, financing, cash sufficiency, share capital, commitments, and financial risks [Note 1: Nature of Operations](index=6&type=section&id=Note%201%3A%20Nature%20of%20Operations) Oncolytics is a clinical-stage biopharmaceutical company developing pelareorep for cancer, funding operations via equity, with sufficient cash for 12 months - The company is a clinical-stage biopharmaceutical firm developing pelareorep, an intravenously delivered immunotherapeutic agent, with a primary focus on advancing programs in HR+/HER2- metastatic breast cancer and pancreatic cancer[12](index=12&type=chunk) - The company has not been profitable since inception and funds operations mainly through issuing capital. As of March 31, 2023, the accumulated deficit was **$424.7 million**[13](index=13&type=chunk) - As of March 31, 2023, the company had cash, cash equivalents, and marketable securities of **$29.7 million**, which it believes is sufficient to fund operations for at least the next twelve months[13](index=13&type=chunk) [Note 6: Share Capital](index=9&type=section&id=Note%206%3A%20Share%20Capital) The company raised **$5.55 million** (US$4.1 million) in Q1 2023 through ATM share sales, part of a larger **US$65 million** offering program - In Q1 2023, the company sold **2,663,036 common shares** under its ATM agreement for gross proceeds of **$5,552,000** (**US$4,100,000**) at an average price of **$2.08 per share**[33](index=33&type=chunk) - The current ATM agreement, established in June 2022, allows the company to issue common shares with an aggregate offering value of up to **US$65 million** over a 25-month period[33](index=33&type=chunk) [Note 9: Commitments](index=11&type=section&id=Note%209%3A%20Commitments) As of March 31, 2023, the company has approximately **$16.6 million** in financial commitments for clinical trials and manufacturing - The company is committed to payments totaling approximately **$16,600,000** for activities mainly related to its clinical trial and manufacturing programs, expected to occur over the next three years[40](index=40&type=chunk) [Note 10: Capital Disclosures](index=11&type=section&id=Note%2010%3A%20Capital%20Disclosures) Capital management supports R&D via equity issuances, leveraging a shelf prospectus for up to **$150 million** in securities until July 2024 - The company's objective is to maintain a strong statement of financial position to support its clinical trial program, manufacturing, and other costs, primarily through obtaining cash resources via equity financing[41](index=41&type=chunk) - In June 2022, the company renewed its short form base shelf prospectus, qualifying for the distribution of up to **$150,000,000** of securities in Canada and/or the U.S. until July 16, 2024[45](index=45&type=chunk)[47](index=47&type=chunk) [Note 11: Financial Instruments](index=13&type=section&id=Note%2011%3A%20Financial%20Instruments) The company manages credit, foreign exchange, and liquidity risks; a **$0.01** USD/CAD increase would decrease net loss by **$231,000** - The company is primarily exposed to foreign exchange risk from the U.S. dollar. As of March 31, 2023, it held a net position of **US$18.3 million** in financial instruments[55](index=55&type=chunk)[56](index=56&type=chunk) - A hypothetical **$0.01** increase in the value of the U.S. dollar against the Canadian dollar would have decreased the company's net comprehensive loss in 2023 by approximately **$231,000**[55](index=55&type=chunk) - Credit risk is managed by holding cash with Schedule I banks in Canada and restricting investments to investment-grade securities with short-term maturities[51](index=51&type=chunk)[52](index=52&type=chunk) [Note 13: Components of Expenses](index=15&type=section&id=Note%2013%3A%20Components%20of%20Expenses) Q1 2023 R&D expenses were **$3.5 million** (down from **$3.7 million**), while G&A increased to **$3.2 million** (up from **$2.6 million**) Expense Breakdown for Q1 (in thousands of Canadian dollars) | Expense Category | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | **Research and Development** | | | | Clinical trial expenses | $909 | $1,093 | | Personnel-related expenses | $1,380 | $1,226 | | **Total R&D Expenses** | **$3,539** | **$3,708** | | **General and Administrative** | | | | Public company-related expenses | $2,201 | $1,564 | | Office expenses | $774 | $660 | | **Total G&A Expenses** | **$3,195** | **$2,602** |

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, Investor Relations and Communications Matt Coffey - Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head, Business Development Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Welcome to Oncolytics Biotech’s Fourth Quarter and Full Ye ...

PART I [Key Information](index=7&type=section&id=Item%203.%20Key%20Information) This section outlines significant investment risks, focusing on product development, financial condition, and funding [Risk Factors](index=7&type=section&id=D.%20Risk%20Factors) The company identifies numerous material risks, including early R&D stage, clinical trial failures, reliance on third parties, and financing needs - The company's lead product, pelareorep, is in the research and development stage, requiring significant further testing before it can be commercially marketed[17](index=17&type=chunk)[26](index=26&type=chunk) - The company relies on third-party drugs for its combination therapies and has limited control over their supply, which could delay product development if collaborations are unsuccessful[17](index=17&type=chunk)[34](index=34&type=chunk) - The company has a history of losses, with an accumulated deficit of **$418.3 million** as of December 31, 2022, and anticipates needing additional financing to fund future research and development[18](index=18&type=chunk)[47](index=47&type=chunk)[50](index=50&type=chunk) - The company believes it was classified as a passive foreign investment company (PFIC) for the 2022 tax year, which may have adverse U.S. federal income tax consequences for U.S. shareholders[19](index=19&type=chunk)[130](index=130&type=chunk) [Information on the Company](index=31&type=section&id=Item%204.%20Information%20on%20the%20Company) Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep for cancer treatment, focusing on clinical trials and strategic partnerships [History and Development of the Company](index=31&type=section&id=A.%20History%20and%20Development%20of%20the%20Company) Oncolytics Biotech Inc. was incorporated in Alberta, Canada on April 2, 1998, with its principal business in Calgary - The company was incorporated in Alberta, Canada on April **2**, **1998**[139](index=139&type=chunk) [Business Overview](index=31&type=section&id=B.%20Business%20Overview) The company develops pelareorep, an immunotherapeutic agent for cancer, advancing clinical programs for breast and pancreatic cancers, and leveraging its patent portfolio - Oncolytics is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the immune system to fight cancer[141](index=141&type=chunk) - The primary strategic focus is advancing pelareorep programs for hormone receptor-positive / human epidermal growth factor **2**-negative (HR+/HER2-) metastatic breast cancer (mBC) and advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) to Phase **3** studies[146](index=146&type=chunk) - Pelareorep's mechanism of action is threefold: selective viral replication leading to tumor cell lysis, activation of innate immunity (NK cells), and priming a specific adaptive immune response (T cells) against tumors[149](index=149&type=chunk) - Interim results from the GOBLET study's pancreatic cancer cohort showed an Objective Response Rate (ORR) of **69%** and a Clinical Benefit Rate (CBR) of **85%**, substantially higher than historical controls[151](index=151&type=chunk)[168](index=168&type=chunk) - The company holds a robust intellectual property portfolio with **243** issued patents globally, covering compositions of matter, pharmaceutical use, combination therapies, and manufacturing methods for reovirus[170](index=170&type=chunk)[172](index=172&type=chunk) [Organizational Structure](index=41&type=section&id=C.%20Organizational%20Structure) As of December 31, 2022, Oncolytics Biotech Inc. operates through its wholly-owned subsidiaries in Barbados and the U.S - The company's main subsidiaries are Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc[194](index=194&type=chunk) [Property, Plant and Equipment](index=41&type=section&id=D.%20Property,%20Plant%20and%20Equipment) The company leases all its office spaces in Calgary, San Diego, and Barbados, owning no manufacturing facilities or real estate - The company leases all its office spaces and does not own any real estate or manufacturing facilities[195](index=195&type=chunk) [Operating and Financial Review and Prospects](index=41&type=section&id=Item%205.%20Operating%20and%20Financial%20Review%20and%20Prospects) This section discusses operating results, liquidity, capital resources, and R&D activities, noting future expenditures are uncertain and depend on funding - The company's Management Discussion and Analysis (MD&A) for **2022** is incorporated by reference to provide details on operating results and liquidity[199](index=199&type=chunk)[200](index=200&type=chunk) - Future expenditures are subject to significant uncertainty, depending on the timing and costs of R&D activities and the availability of funding[202](index=202&type=chunk) [Directors, Senior Management and Employees](index=42&type=section&id=Item%206.%20Directors,%20Senior%20Management%20and%20Employees) This section details leadership, compensation, board practices, and employee statistics, including equity compensation plans and share ownership [Directors and Senior Management](index=42&type=section&id=A.%20Directors%20and%20Senior%20Management) The report lists directors and senior management as of December 31, 2022, including their positions and share ownership - As of February **27**, **2023**, the directors and senior management as a group beneficially owned **847,866** common shares, representing **1.35%** of the issued and outstanding shares[210](index=210&type=chunk) [Compensation](index=46&type=section&id=B.%20Compensation) Details of 2022 compensation for directors and senior management are provided, including base retainers, bonuses, and equity awards | Name | Position | Salary ($) | Option-based awards ($) | Bonus ($) | Total compensation ($) | | :--- | :--- | :--- | :--- | :--- | :--- | | Dr. Matthew C. Coffey | President and CEO | 654,404 | 136,616 | 310,842 | 1,185,060 | | Kirk J. Look | CFO | 486,593 | 109,293 | 184,905 | 850,145 | | Dr. Thomas C. Heineman | CMO | 599,999 | 109,293 | 228,000 | 981,971 | - Non-employee directors receive a base retainer of **US$40,000**, with additional retainers for the Board Chair (**US$40,000**) and committee chairs (**US$10,000**-**US$20,000**)[217](index=217&type=chunk) - Employment agreements include severance provisions. In the event of a change of control, the CEO would be entitled to a severance payment of **$1,475,205**, and the CFO would be entitled to **$1,111,894**, as of December **31**, **2022**[228](index=228&type=chunk)[229](index=229&type=chunk) [Employees](index=52&type=section&id=D.%20Employees) The company's workforce grew from 25 in 2020 to 29 in 2022, with employees split between R&D and general/administrative functions | Year | Total Employees | R&D | General & Admin | | :--- | :--- | :--- | :--- | | 2022 | 29 | 17 | 12 | | 2021 | 26 | 15 | 11 | | 2020 | 25 | 14 | 11 | [Share Ownership](index=54&type=section&id=E.%20Share%20Ownership) This subsection details common share and stock option holdings of directors and officers, and describes the company's equity compensation plans - As of February **27**, **2023**, directors and officers collectively held **847,866** common shares and **4,034,942** outstanding options[249](index=249&type=chunk)[250](index=250&type=chunk) - The company's Stock Option Plan and Share Award Plan combined cannot exceed **10%** of the total number of issued and outstanding Common Shares[254](index=254&type=chunk)[267](index=267&type=chunk) [Major Shareholders and Related Party Transactions](index=59&type=section&id=Item%207.%20Major%20Shareholders%20and%20Related%20Party%20Transactions) The company reports no shareholders owning over 5% of voting shares and no material related party transactions for the fiscal year - As of March **3**, **2023**, the company is not aware of any shareholder beneficially owning more than **5%** of its voting shares[274](index=274&type=chunk) | Date | Total Shares Outstanding | U.S. Holders of Record | Shares Held by U.S. Holders | % Held by U.S. Holders | | :--- | :--- | :--- | :--- | :--- | | Feb 24, 2023 | 62,826,958 | 59 | 54,495,601 | 86.74% | [Financial Information](index=60&type=section&id=Item%208.%20Financial%20Information) This section confirms consolidated financial statements are filed under Item 18, reports no material legal proceedings, and states no dividends will be paid - The company has not paid any dividends since its incorporation and does not intend to in the foreseeable future, retaining earnings to finance growth[284](index=284&type=chunk) - There are no material, active, or pending legal proceedings against the company, its directors, or management[283](index=283&type=chunk) [Additional Information](index=61&type=section&id=Item%2010.%20Additional%20Information) This section covers corporate governance, Canadian exchange controls, and material Canadian and U.S. federal income tax considerations for shareholders - The company is governed by the Business Corporations Act of Alberta. A quorum for shareholder meetings requires representation of at least **5%** of issued and outstanding shares[289](index=289&type=chunk)[295](index=295&type=chunk) - Canada has no system of exchange controls, but acquisitions of 'control' (generally **one-third** or more of voting shares) by a non-Canadian may require review under the Investment Canada Act[301](index=301&type=chunk)[302](index=302&type=chunk) - Dividends paid to non-resident holders are subject to a **25%** Canadian withholding tax, which may be reduced by applicable tax treaties (e.g., to **15%** for eligible U.S. residents)[311](index=311&type=chunk) - The company believes it was a Passive Foreign Investment Company (PFIC) for the **2022** tax year, which has significant and potentially adverse U.S. federal income tax implications for U.S. Holders, who are advised to consult their tax advisors[322](index=322&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=76&type=section&id=Item%2011.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company discloses exposure to credit, interest rate, and foreign exchange risks, noting it does not use financial instruments for trading or hedging - The company does not currently have long-term debt or use derivative instruments for hedging against interest rate or other market risks[368](index=368&type=chunk) PART II [Controls and Procedures](index=76&type=section&id=Item%2015.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2022 - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the fiscal year **2022**[373](index=373&type=chunk) - Management assessed the company's internal control over financial reporting as effective as of December **31**, **2022**, using the COSO framework[376](index=376&type=chunk) [Corporate Governance](index=78&type=section&id=Item%2016G.%20Corporate%20Governance) As a foreign private issuer, the company follows Canadian corporate governance practices, which differ from Nasdaq's requirements, notably in quorum rules - As a foreign private issuer, the company is exempt from certain Nasdaq corporate governance rules and follows Canadian practices[388](index=388&type=chunk) - A significant governance difference is the shareholder meeting quorum, which is **5%** of outstanding shares, lower than the Nasdaq minimum requirement of **one-third**[389](index=389&type=chunk) PART III [Financial Statements](index=83&type=section&id=Item%2018.%20Financial%20Statements) This section contains audited consolidated financial statements for 2022, showing a net loss of **$24.8 million** and an unqualified auditor opinion [Consolidated Statements of Financial Position](index=86&type=section&id=Consolidated%20Statements%20of%20Financial%20Position) As of December 31, 2022, total assets decreased to **$37.3 million**, total liabilities increased to **$10.8 million**, and equity decreased to **$26.5 million** | (in thousands of CAD) | Dec 31, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $11,666 | $41,262 | | Marketable securities | $20,472 | $0 | | **Total Assets** | **$37,334** | **$45,880** | | Total current liabilities | $3,945 | $2,690 | | **Total Liabilities** | **$10,832** | **$9,781** | | Accumulated deficit | ($418,251) | ($393,416) | | **Total Shareholders' Equity** | **$26,502** | **$36,099** | [Consolidated Statements of Loss and Comprehensive Loss](index=87&type=section&id=Consolidated%20Statements%20of%20Loss%20and%20Comprehensive%20Loss) For 2022, the company reported a net loss of **$24.8 million**, a decrease from **$26.3 million** in 2021, primarily due to lower G&A expenses | (in thousands of CAD) | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | Research and development | $15,432 | $12,920 | $12,945 | | General and administrative | $11,492 | $13,315 | $12,514 | | **Net Loss** | **($24,835)** | **($26,304)** | **($22,505)** | | **Loss per common share** | **($0.43)** | **($0.49)** | **($0.56)** | [Consolidated Statements of Cash Flows](index=89&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) In 2022, cash used in operations was **$23.4 million**, resulting in a net decrease of **$31.6 million**, with year-end cash at **$11.7 million** | (in thousands of CAD) | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | Cash used in operating activities | ($23,355) | ($22,433) | ($22,068) | | Cash used in investing activities | ($20,403) | ($286) | ($29) | | Cash provided by financing activities | $12,205 | $33,015 | $39,773 | | **(Decrease) increase in cash** | **($31,553)** | **$10,296** | **$17,676** | | **Cash, end of year** | **$11,666** | **$41,262** | **$31,220** |